AI Powered Genomics
Genomic Data +AI: A New Era of Precision Medicine.
柏霖智生 | GenetrixBio
A leading innovator in the AI-driven healthcare field, dedicated to transforming traditional medical models and advancing the intelligent evolution of the industry.
Our Technology and Advantages
By leveraging cutting-edge machine learning and deep learning algorithms, we analyze and extract insights from vast amounts of medical data to develop highly efficient and precise AI solutions.
Our technology spans the entire medical service spectrum, from early disease detection to personalized precision medicine and drug efficacy prediction.
Through close collaboration with medical institutions and research organizations, we continuously refine and optimize our products, ensuring their clinical practicality and reliability. We empower patients with more accurate, effective medical solutions, driving progress and innovation in the field of precision medicine.
The company brings together a global team of leading experts in genomics, bioinformatics, translational medicine, clinical medicine, and other fields. We are dedicated to building a precision medicine ecosystem driven by early disease screening, multiomics analysis, clinical services, CDx development, and advanced AI algorithms.
Our core team members average over 12 years of R&D experience in global biopharma companies. They have spearheaded the development of over 30 IVD products and led global multi-center clinical trials, including FDA/NMPA dual-approval projects. This expertise empowers us to deliver a full-service ecosystem, from multi-gene panel design and AI algorithm development to clinical validation.
Driven by the principle of 'technology as the foundation, data as the driving force,' we enhance evidence-based decision support, accelerate drug development with innovative algorithms, and refine clinical practices through precise diagnostics, with our technology and algorithms as the core drivers of progress.
Products and Services
OncoDx™
Genetic testing solution powered by NGS technology enable comprehensive analysis of hundreds of genes simultaneously to inform personalized treatment.
- Comprehensive detection of tumor-related gene mutations, with precise identification of cancer driver genes and drug-resistant mutations.
- Real-time tumor monitoring enables timely adjustment of treatment strategies, enhancing treatment accuracy.
- Support precision immunotherapy through combined detection of immunotherapy markers.
- Accurate identification of tumor molecular characteristics to guide the selection of the most effective targeted therapies, enabling personalized treatment.
- Study tumor progression to detect and prevent metastasis and recurrence at an early stage.
OncoWES™
Genetic testing solution powered by NGS technology enable comprehensive analysis of all the protein-coding regions of the genome, providing a complete understanding of mutation data.
- Pan-cancer target heat map to guide the development of broad-spectrum anti-cancer therapies.
- Uncover the genetic basis of complex diseases, offering novel insights for early prediction, prevention, and treatment strategies.
- Provide valuable resources for target discovery, identifying key genes and molecular pathways involved in tumor development, and pinpointing potential drug target candidates.
- Gain a deeper understanding of drug mechanisms and resistance, elucidating adaptive variations to guide the structural optimization of drug molecules.
- Develop a comprehensive knowledge base of gene-drug interactions to predict off-label indications and enhance drug efficacy.
OncoMRD™
Tumor-informed Molecular Residual Disease (MRD) testing, utilizing prior tissue genetic analysis to design personalized ctDNA MRD testing, helping the early detection of cancer relapse
- Patients with residual or recurrent disease post-surgery can benefit most from adjuvant therapy
- Early detection of molecular residues enables timely intervention, improving patient prognosis
- Investigate drug resistance mechanisms, refine treatment strategies, and extend patient survival
OncoGuard™ | Cancer Early Detection
Liver cancer screening: 95.42% sensitivity, 97.91% specificity, with detection of very early-stage micro-liver cancer up to 6-12 months in advance.
Multi-cancer screening: Early detection of six high-risk cancers—lung, gastric, esophageal, colorectal, liver, and pancreatic—with 87.58% sensitivity, 99.09% specificity, and 82% origin prediction accuracy.
- Integrating multi-dimensional omics data with AI algorithms to extract, iterate, and refine features, enabling precise detection of tumor signals in plasma cfDNA.
- Built on whole genome sequencing, it provides comprehensive information for feature screening, offering significant flexibility for model optimization and expansion into various applications.
- Leveraging large-scale clinical cohort and validated through extensive retrospective and prospective data, the model demonstrates stable, superior performance.
- The detected signals contain tissue-specific information, making it a versatile method for broadening early screening from single tumor to multiple cancer types.
MOFA™ | Multi-Omics Fusion Analysis
Multi-Omics Fusion Analysis integrates genomics, transcriptomics, proteomics, and metabolomics to deliver comprehensive bioinformatics. Our solutions combine NGS, MS, and advanced algorithms for precise insights from genetic variation to phenotypic regulation.
- Comprehensive Analysis: Multi-level biological system analysis that uncovers molecular networks, enhancing disease diagnosis and mechanism understanding.
- Precision: Ensures data accuracy and reproducibility using leading platforms and algorithms.
- Customized Solutions: Offers flexible integration of omics data for tailored research strategies.
- Data Mining: Utilizes AI and knowledge graphs for in-depth pathway analysis, advancing target discovery and drug research.
Customized Services
The company has established end-to-end R&D capabilities in biomarker detection, drug therapy monitoring, and early cancer screening. With deep expertise in precision medicine, it provides customized development services to global pharmaceutical firms and research institutions. Its proprietary verification system and multi-gene algorithm platform support early drug target screening, translational research, enabling precise patient selection and CDx development, etc.
IVD Development Services
Whether you are engaged in the iterative upgrade of IVD testing, the frontier exploration of companion diagnostic technology, or the precise construction of clinical trial application testing, we can tailor a unique IVD development service solution for you with our top professional strength and rich experience in the industry. Our end-to-end integrated service covers the entire life cycle of IVD testing development, from the initial testing conception, to rigorous design and development, strict verification and confirmation process, to the efficient delivery of the final product, and deeply participates in every key link.
- Using genomic data to support biopharmas in the design and execution of clinical trials
- Employing advanced multi-platform technologies to deliver rich product lines
- Extensive development experience and robust and thorough verification process
- Customized panels to meet diverse and specific needs
- AI-powered algorithm models that enhance and optimize the detection process
- Strong network of hospital collaborations ensuring efficient resource access
Contact Us
Location:
Life Science Park, Changping District, Beijing
Email:
communications@genetrixbio.com